BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BYSI
CUSIPN/A
Phone646-528-4184
Debt
Debt-to-Equity RatioN/A
Current Ratio6.75
Quick Ratio6.75
Price-To-Earnings
Trailing P/E Ratio-6.14
Forward P/E Ratio-9.56
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.23 per share
Price / Book21.77
Profitability
EPS (Most Recent Fiscal Year)($4.40)
Net Income$-91,760,000.00
Net MarginsN/A
Return on Equity-224.65%
Return on Assets-208.02%
Miscellaneous
Employees25
Outstanding Shares22,440,000
Beyondspring (NASDAQ:BYSI) Frequently Asked Questions
What is Beyondspring's stock symbol?
Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."
How were Beyondspring's earnings last quarter?
Beyondspring Inc (NASDAQ:BYSI) released its earnings results on Thursday, June, 21st. The company reported ($0.61) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.73) by $0.12. View Beyondspring's Earnings History.
When is Beyondspring's next earnings date?
What price target have analysts set for BYSI?
4 brokers have issued 12-month target prices for Beyondspring's stock. Their forecasts range from $48.00 to $60.00. On average, they anticipate Beyondspring's share price to reach $53.50 in the next year. View Analyst Ratings for Beyondspring.
What are Wall Street analysts saying about Beyondspring stock?
Here are some recent quotes from research analysts about Beyondspring stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating with a $60 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (6/22/2018)
- 2. Maxim Group analysts commented, "We maintain our Buy rating on BeyondSpring (BYSI), though lower our price target to $48, from $52, following the release of 1Q18 (March) results." (6/21/2018)
- 3. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (6/5/2018)
Who are some of Beyondspring's key competitors?
Some companies that are related to Beyondspring include Arena Pharmaceuticals (ARNA), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Global Blood Therapeutics (GBT), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), Puma Biotechnology (PBYI), Prestige Brands (PBH), Akorn (AKRX), Phibro Animal Health (PAHC) and Corcept Therapeutics (CORT).
Who are Beyondspring's key executives?
Beyondspring's management team includes the folowing people:
- Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 47)
- Mr. Dongheng Liu, Chief Financial Officer (Age 36)
- Ms. Amy Yang, Controller
- Dr. Ramon W. Mohanlal, Chief Medical Officer of BeyondSpring U.S. (Age 60)
- Dr. G. Kenneth Lloyd, Chief Scientific Officer of BeyondSpring U.S. (Age 74)
When did Beyondspring IPO?
(BYSI) raised $4 million in an IPO on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.
Has Beyondspring been receiving favorable news coverage?
Press coverage about BYSI stock has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Beyondspring earned a media sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the company an impact score of 45.93 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Beyondspring?
Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Beyondspring's stock price today?
One share of BYSI stock can currently be purchased for approximately $26.78.
How big of a company is Beyondspring?
Beyondspring has a market capitalization of $605.76 million. The company earns $-91,760,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. Beyondspring employs 25 workers across the globe.
How can I contact Beyondspring?
Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-528-4184 or via email at [email protected]
MarketBeat Community Rating for Beyondspring (BYSI)
MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
